Next Article in Journal
Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy
Next Article in Special Issue
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
Previous Article in Journal
Purine-Metabolising Enzymes and Apoptosis in Cancer
Previous Article in Special Issue
The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer
Open AccessReview

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

1
Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, Italy
2
Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy
3
Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
4
CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Malaga, Spain
5
Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1355; https://doi.org/10.3390/cancers11091355
Received: 14 August 2019 / Revised: 5 September 2019 / Accepted: 10 September 2019 / Published: 12 September 2019
(This article belongs to the Special Issue Prostate Cancer: Past, Present, and Future)
The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient’s risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers. View Full-Text
Keywords: hormone-sensitive prostate cancer; hormone-naïve prostate cancer; docetaxel; enzalutamide; abiraterone acetate; apalutamide; radiotherapy hormone-sensitive prostate cancer; hormone-naïve prostate cancer; docetaxel; enzalutamide; abiraterone acetate; apalutamide; radiotherapy
MDPI and ACS Style

Cattrini, C.; Castro, E.; Lozano, R.; Zanardi, E.; Rubagotti, A.; Boccardo, F.; Olmos, D. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers 2019, 11, 1355.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop